# Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

> **NCT02517905** · PHASE3 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 166 (actual)

## Conditions studied

- Dental Pain

## Interventions

- **DRUG:** Bupivacaine liposome
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02517905
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2020-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517905, "Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02517905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*